HAIER BIOMEDICAL(SH:688139)2022-03-24 16:00Financial Performance - The company's operating revenue for 2021 was CNY 2,125,862,739.15, representing a year-on-year increase of 51.63%[30]. - The net profit attributable to shareholders for 2021 was CNY 845,035,305.76, a significant increase of 121.82% compared to the previous year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 32.97% to CNY 418,046,340.77 in 2021[30]. - Basic earnings per share for 2021 rose to CNY 2.67, reflecting a year-on-year growth of 122.50%[33]. - The total profit reached 960.87 million RMB, with a year-on-year increase of 126.49%[47]. - The company's cash flow from operating activities decreased by 15.05% to CNY 591,798,010.34 due to increased cash payments for inventory and services[34]. - The gross profit margin decreased to 50.08%, down by 0.51 percentage points due to rising costs of raw materials[163]. Dividend Distribution - The company plans to distribute a cash dividend of 5.0 RMB per 10 shares, totaling approximately 158.2 million RMB, which represents 18.72% of the net profit attributable to shareholders for 2021[7]. - As of December 31, 2021, the total share capital of the company was 317,071,758 shares, with 316,391,758 shares eligible for the dividend after excluding repurchased shares[7]. Research and Development - Research and development expenses accounted for 11.12% of operating revenue in 2021, up from 10.75% in 2020[33]. - R&D expenses amounted to ¥236,307,039.02, representing a 56.79% increase compared to the previous year's ¥150,719,187.87[116]. - The company applied for 269 new patents and obtained 197 authorizations in 2021, totaling 539 patents by the end of December 2021[109]. - The company has established a comprehensive open innovation system, enhancing its competitive edge in the biomedical low-temperature storage and biosafety solution sectors[142]. Market Expansion and User Engagement - The company plans to continue expanding its global market presence and enhancing its product innovation through increased R&D investment[34]. - The company is actively pursuing global market expansion, with multiple products certified by international standards such as NSF/ANSI and DIN[51]. - The company expanded its user base significantly, doubling the number of users in niche areas such as CXO, cell therapy, and gene therapy[49]. - The company is deepening its global market presence by establishing localized teams and systems to better understand and meet user needs, thereby increasing global market share[199]. Operational Risks and Governance - The company has outlined various operational risks and corresponding mitigation measures in the management discussion and analysis section of the report[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[10]. - The company has not disclosed any special arrangements for corporate governance[10]. Technological Advancements - The company has made significant technological advancements, including breakthroughs in automation, microbial culture, environmental simulation, and rapid cooling centrifugation technologies[66]. - The company has developed a comprehensive low-temperature storage solution for biomedical applications, covering sample safety, drug safety, vaccine safety, and blood safety, and has achieved a breakthrough in low-temperature technology, breaking foreign monopolies[66]. - The company launched innovative IoT solutions for blood safety management and vaccine storage, enhancing user experience and supporting the upgrade of the medical industry[93]. Employee and Talent Development - The workforce increased to over 2,000 employees, with 78% of new hires in R&D and marketing roles, strengthening the talent pool[62]. - The company has implemented a diverse employee incentive mechanism, including a restricted stock incentive plan launched in 2021, aimed at attracting and retaining talent[65]. - The company has established a talent reserve pool and a tiered training system to continuously stimulate employee potential and maintain innovation vitality[65]. Compliance and Standards - The company has led or participated in drafting 19 national, industry, and group standards, promoting the standardized development of the industry[66]. - The company participated in the formulation of six national standards, including those for automated low-temperature biological sample banks and vaccine cold chain logistics, establishing industry leadership[114]. Investment and Financial Management - The company’s investment activities resulted in a net cash outflow of CNY 1,501,417,001.14, a significant increase of 1,010.33% compared to the previous year[160]. - The company is actively managing foreign exchange risks through hedging strategies and locking in exchange rates[152]. - The company recognized a gain from the disposal of 17.11% equity in the associate company Mesa during the reporting period[177].